Co-founder and CSO Ryan Murray's PhD research was published in Nature Communications.
The study examined coordinated engineering against allogeneic rejection and overlapping suppressive mechanisms in solid tumors. Its findings are consistent with KiraGen's focus on evaluating multiplex edits as integrated cell-therapy architectures.